Conference Day Two

Conference Day Two | Thursday, October 23, 2025

7:50 am Check In & Light Breakfast

8:50 am Chair’s Opening Remarks

Advancing Spatial Multi-Omics & Practical Lab Infrastructure to Provide Novel Insights into Complex Inflammatory Diseases

9:00 am Spatial Multi-Omics of Crohn’s Disease: Advancing Pathobiology & Target Discovery in Biopharma

Synopsis

  • Highlighting the application of cutting-edge spatial omics technologies – including spatial transcriptomics, single-nucleus RNA sequencing, and high-order multiplexed protein imaging – to study the complex pathobiology of Crohn’s disease using FFPE tissue
  • Integrating spatial and single-cell data with histological annotation, we reveal distinct epithelial states, immune-stromal interactions, and ulcer-associated transcriptional programs that inform therapeutic hypothesis generation
  • Harnessing this multi-omics approach enables high-resolution, spatially contextualized insights directly from archived clinical samples, offering a powerful platform for target discovery and translational research in chronic inflammatory diseases

9:30 am Building Internal Spatial Biology Infrastructure: Lessons from Multi- Platform Implementation in Ulcerative Colitis Research

  • Tim Holzer Executive Director, Clinical Diagnostics Laboratory, Eli Lilly

Synopsis

  • Systematic multi-platform comparative studies of workflow requirements and output metrics to inform critical laboratory infrastructure decisions
  • Implementation of pathologist-guided tissue quality reviews along with RNA quality assessments
  • Application to studies of ulcerative colitis, assessments of intestinal fibrosis, and custom analytical tools to compare data across technologies

NEW DATA!

10:00 am Morning Networking Break

Unlocking Spatial Insights to Drive Mechanistic Understanding & Target Discovery to Catalyse Novel Therapeutic Breakthroughs

11:00 am Application of Spatial Omics Approaches in Inflammation & Immunology Research

  • Ying Zhang Head - Next Generation Sequencing, Systems & Immunology Group, Pfizer
  • Kai-Chih Huang Senior Computational Scientist, Pfizer

Synopsis

  • Comparing available spatial platforms to understand their strengths, limitations, and suitability for inflammation and immunology studies
  • Showcasing how spatial immune profiling can uncover novel cellular interactions and tissue microenvironments that drive disease mechanisms in inflammatory disorders
  • Demonstrating a spatial multi-omics workflow that integrates transcriptomics, proteomics, and histopathology to generate deeper, actionable insights for target discovery and biomarker development

NEW DATA!

11:30 am Panel Discussion: Leveraging Spatial Biology to Unlock Novel Insights into Complex Disease for Enhanced Therapeutic & Biomarker Development

  • Ying Zhang Head - Next Generation Sequencing, Systems & Immunology Group, Pfizer
  • Tim Holzer Executive Director, Clinical Diagnostics Laboratory, Eli Lilly
  • Subba Chintalacharuvu Executive Director - Translational Immunology, Genentech
  • Sunish Mohanan Senior Director - Research Pathology, Gilead

Synopsis

  • What are some of the most promising ways spatial biology is helping us better understand complex disease mechanisms that traditional approaches may miss?
  • How can we translate novel spatial insights into robust, clinically relevant biomarkers and therapeutic targets that hold up across different patient populations?
  • What practical steps are needed to integrate spatial biology more effectively into discovery and development pipelines?

12:30 pm Lunch Break & Networking

Optimizing Spatial & Single-Cell Strategies to Translate Impactful & Reproducible Results into Clinical Trials

1:30 pm Leveraging Spatial & Single-Cell Approaches for Scalable Insights in Disease Research

  • Yu Tian Director II, Research Development Digital & Data Strategy, AbbVie
  • Fei Wang Postdoctoral fellow, AbbVie

Synopsis

  • Showcasing practical strategies for integrating spatial omics and single-cell sequencing to map disease mechanisms at high resolution
  • Exploring scalable workflows that can be applied across diverse indications
  • Highlighting how robust multi-omics integration drives better understanding of key cellular drivers, pathways, and phenotypes to inform target discovery

NEW DATA!

2:00 pm Transforming Raw Spatial Data into Standardized, Reproducible, & Interoperable Insights to Expedite Spatial Biology Adoption

  • Alexander Klimowicz Principal Scientist Senior Research Fellow & Head of Spatial Biology - Immunology & Respiratory Discovery, Boehringer Ingelheim

Synopsis

  • Building confidence in cell segmentation — and understanding how algorithm choice impacts what you see and miss
  • Aligning cell definitions and annotations across spatial, single-cell, and multi-omics datasets to speak a common language and improve interoperability
  • Reconciling pathology insight with spatial-omics molecular resolution to build robust spatial niches

2:30 pm Bridging Histopathology AI & Spatial Omics for Richer Context, Better Targets & Translational Success

  • Vipul Baxi Executive Director, Computational Imaging & Digital Biomarkers, Amgen

Synopsis

  • Establishing practical strategies for integrating histopathology AI with spatial transcriptomics and proteomics workflows to generate richer, more meaningful data
  • Underpinning key considerations for ensuring data quality, reproducibility, and contextual relevance across therapeutic areas
  • Strategizing how bridging these approaches can strengthen discovery, translational research, and clinical decision-making

NEW COMPANY!

3:00 pm Roundtable Discussion: Scaling Spatial & Single-Cell Workflows to Unlock Consistent, High-Quality Multi-Omics Data to Discover Novel Targets

Synopsis

  • How to expand from small pilots to routine use of spatial and single-cell pipelines across disease programs?
  • What are the practical steps to standardise sampling, assays, and data integration for reproducibility across sites and teams?
  • How to build fit-for-purpose infrastructure and partnerships that reduce variability and deliver reliable insights for drug discovery?

3:30 pm Afternoon Networking Break

Advancing Biomarker Discovery & Development Through Spatial Signatures to Incorporate into Clinical Trials

4:00 pm Leveraging Computational Pathology to Expand Patient Stratification & Biomarker Development in Spatial Biology

  • Guneet Walia Senior Director, Data Science & Digital Health, Johnson & Johnson

Synopsis

  • How AI-driven digital pathology is identifying non-binary biomarkers and expanding patient populations beyond conventional markers
  • Practical strategies for integrating computational pathology into early-phase drug development and translational pipelines
  • Lessons learned in standardizing digital pathology workflows to enable robust spatial biomarker discovery and clinical implementation

4:30 pm Studying T-Cells in a TME with a Combination of 10x Visium HD & Single- Cell Sequencing

Synopsis

  • Identifying tumor-reactive TCRs from single-cell sequencing and in vitro reactivity screening
  • Linking T cell phenotypes and TCR reactivities to TME context through spatial transcriptomics
  • Demonstrating our approach on two cancer samples with very distinct patterns of T cell infiltration

5:00 pm Chair’s Closing Remarks

5:05 pm End of the 3rd Spatial Biology for Drug Development Summit